
Opinion|Videos|January 24, 2024
REACH3: Ruxolitinib in Steroid Refractory cGvHD
Author(s)Robert Zeiser, MD, Nelson J. Chao, MD
Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































